Journal of Medical Oncology and Therapeutics

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +441518081136

POLYPLOID GIANT CANCER CELLS MAY REPRESENT A SOMATIC EQUIVELANT OF BLASTOMERE

11th International Conference on Cancer Stem Cells and Oncology Research
June 11-13, 2018 | Dublin, Ireland

Jinsong Liu and Na Niu

The University of Texas, USA

Posters & Accepted Abstracts : J Med Oncl Ther

Abstract:

It is now generally accepted that all mature somatic cells retain the capability to be reprogrammed (or dedifferentiated) to pluripotent state. However, it remains unclear how the endogenous developmental pathway is activated for such a reprogramming. We have recently shown that chemotherapy drug paclitaxel (PTX) can induce cancer cells undergo senescence and lead the formation of a big monster cells, refer as polyploid giant cancer cells (PGCCs). PGCCs bypass the spindle checkpoint and replicate the DNA without cell division. PGCCs show time- and space-dependent activation of expression of reprogramming factors OCT4, NANOG, and SOX2; lack expression of Xist; and are capable of dedifferentiation. The parental cancer cells are reprogrammed via formation of PGCCs which can give a birth of diploid resistance cancer cells via budding. This division mode recapitulates that of blastomere-to-morula stage embryo and facilitates the dedifferentiation toward the blastomere stage embryonic stem cells. PGCCs use an evolutionarily conserved embryonic program used to reprogram zygote to new embryonic state for for disease relapse and thus represent a somatic equivalent of blastomere. Here, we provide a model on how PGCCs divide and how they achieve the dedifferention, named the blastomere model for cancer and disease relapse. This new conceptual paradigm, which integrates different tumors along bidirectional developmental hierarchy, should facilitate our understanding of cancer origin and to guide our efforts for therapeutic intervention. jliu@mdanderson.org

PDF HTML

Get the App